Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Imugene ( (AU:IMU) ) has shared an update.
Imugene Limited has successfully completed its Share Purchase Plan, raising $2.42 million through the issuance of over 7.3 million shares at $0.33 each. This follows a prior institutional placement that raised $22.5 million. The funds will support Imugene’s ongoing efforts in developing novel cancer therapies, reinforcing its position in the immuno-oncology sector and demonstrating strong investor confidence in its strategic direction.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system in cancer patients. Their platform technologies aim to harness the body’s immune response to target and eliminate tumors, with a pipeline that includes cell therapy CAR T drugs and oncolytic virotherapy. Imugene collaborates with international cancer experts to transform cancer treatment and improve patient outcomes.
Average Trading Volume: 1,709,987
Technical Sentiment Signal: Sell
Current Market Cap: A$75.01M
Learn more about IMU stock on TipRanks’ Stock Analysis page.